Noom, an online weight loss company, is unveiling its Microdose GLP-1 Rx Program, a service intended to limit side effects via personalized microdoses of GLP-1s, when clinically appropriate of course
What the data shows for GLP-1 medications Analyses from GLP-1 trial data indicate that approximately 2540% of weight lost on semaglutide and tirzepatide is lean mass rather than fat mass
Your food choices, activity level, gut health, and blood sugar patterns can influence your bodys natural GLP-1 response
As these therapies evolve, primary care will be at the forefront of integrating them into holistic, patient-centered management, says Kyle Lee, BMLSc, BMBS, MPH, CCFP, Sermo medical advisory board member, in a release